5-methoxy-4-oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic acid ethyl ester | 223666-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 菲咯啉
• 英文名称: 5-methoxy-4-oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic acid ethyl ester
• 英文别名: 5-Methoxy-4-oxo-1,4-dihydro-[1,10]phenanthrolin-3-carbonsaeure-aethylester；ethyl 5-methoxy-4-oxo-1H-1,10-phenanthroline-3-carboxylate
• CAS: 223666-22-6；38559-18-1
• 化学式: C₁₆H₁₄N₂O₄
• 分子量: 298.298
• InChiKey: ZLINHHQQUVYYEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-methoxy-4-oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic acid ethyl ester 在 二苯醚 、 五氯化磷 、 三氯氧磷 作用下， 生成 4-chloro-5-methoxy-[1,10]phenanthroline
  参考文献：
  名称：

  Some Substituted 1,10-Phenanthrolines¹

  摘要：

  DOI：

  10.1021/ja01211a065
• 作为产物：
  描述：

  8-氨基-6-甲氧基喹啉 在 二苯醚 作用下， 生成 5-methoxy-4-oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Some Substituted 1,10-Phenanthrolines¹

  摘要：

  DOI：

  10.1021/ja01211a065

文献信息

• Stabilization of hypoxia inducible factor (HIF) alpha
  申请人：FIBROGEN, INC.

  公开号：EP2295059A2

  公开（公告）日：2011-03-16

  The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.

  本发明涉及稳定缺氧诱导因子（HIF）α亚基的方法。本发明进一步涉及预防、预处理或治疗与 HIF 相关的病症（包括缺血和缺氧病症）的方法。本发明还提供了用于这些方法的化合物。
• Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10098857B2

  公开（公告）日：2018-10-16

  Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

  通过透皮给药增加伤口中 HIF-1α 的活性，提供了预防和治疗慢性伤口（包括但不限于压疮和糖尿病溃疡）的组合物和方法。
• HIF-1 modulator paint formulation and uses thereof
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10220009B2

  公开（公告）日：2019-03-05

  Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.

  为改善实体器官移植的功能（即临床结果）提供了制剂和方法。肺移植尤其值得关注。在本发明的方法中，一种纳米颗粒制剂包括有效剂量的纳米颗粒形式的铁螯合剂活性剂，包括但不限于悬浮在与相关组织相容的载体中的去铁胺（DFO）、去铁胺（DFX）和去铁酮（DFP）等，局部应用于吻合部位的组织表面。纳米颗粒由活性剂和药学上可接受的稳定剂组成。
• Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
  申请人：Crabtree Sue Judy

  公开号：US20060216295A1

  公开（公告）日：2006-09-28

  Disclosed herein are methods for the identification of effector molecules useful in the treatment of vulvovaginal atrophy. Methods of treating vulvovaginal atrophy comprising administering the effector molecules are also disclosed.

  本文公开了用于治疗外阴阴道萎缩的效应分子的鉴定方法。还公开了通过施用效应分子治疗外阴阴道萎缩的方法。
• STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA
  申请人：FIBROGEN, INC.

  公开号：EP1487472A2

  公开（公告）日：2004-12-22